OncoMatch/Clinical Trials/NCT07188584
Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer
Is NCT07188584 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for nasopharyngeal carcinoma (npc).
In order to further verify the effectiveness of the new prevention irradiation model for low-risk areas for nasopharyngeal carcinoma under immunotherapy, our team intends to conduct a non-inferiority clinical trial. The aim is to evaluate the efficacy and safety of two treatment modalities - local region reduced-target radiotherapy versus full-target radiatiotherapy (with/without CTV2) for newly diagnosed distant metastasis nasopharyngeal carcinoma, based on the full-course immunotherapy and full-dose chemotherapy. The primary endpoints are 2-year PFS and the incidence of grade 3 or higher radiation-related adverse events. If non-inferiority is confirmed, a new standard of "immunotherapy combined with reduced-target radiotherapy" will be established, ensuring efficacy while significantly reducing toxicity, and providing a more optimal comprehensive treatment strategy for nasopharyngeal carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage TANYNANYM1, IVB (AJCC 9th edition)
Metastatic disease required
Clinical stage: TanyNanyM1, stage IVB (AJCC 9th edition)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — first-line
adequate first-line systematic therapy (platinum-containing doublet chemotherapy + PD-1 monoclonal antibody)
Must have received: anti-PD-1 therapy — first-line
adequate first-line systematic therapy (platinum-containing doublet chemotherapy + PD-1 monoclonal antibody)
Lab requirements
Cardiac function
no grade ≥ ii coronary heart disease, arrhythmia (including qtc interval prolongation in males > 450 ms, females > 470 ms) and heart failure
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify